Geneva (Switzerland), 12 june 2017 – 7:30am CEST : – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today data supporting the link between human endogenous retroviruses (HERVs) and Type 1 diabetes (T1D). Data were presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA (June 9-13, 2017).
Further information can be found at :
https://www.geneuro.com/data/news/geneuro-pr-20170612-ada-eng.pdf
